UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 15, 2021
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (201 )
478-5552
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
|
- |
|
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On October 15, 2021, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Young T. Kwon, Ph.D. to serve on the Board
as a Class II director with a term expiring at the Company’s 2024 annual meeting of stockholders.
Dr. Kwon currently serves as an Operating Partner of Lightstone Ventures. Prior to this, Dr. Kwon served in roles of increasing responsibility at
Momenta Pharmaceuticals Inc. (“Momenta”), including Chief Financial and Business Officer from January 2020 to January 2021, Chief Business Officer from October 2018 to January 2020, Senior Vice President, Corporate Development and Strategy from
August 2015 to October 2018 and Vice President, Corporate Development and Strategy from January 2011 to July 2015. Prior to joining Momenta, Dr. Kwon was Senior Director of Business Development at Biogen Idec, where he led corporate development
activities, including evaluation of a variety of transactions. Dr. Kwon received his B.S. from the Massachusetts Institute of Technology in 1994 and his Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University in 1999.
There is no arrangement or understanding between Dr. Kwon and any other person pursuant to which Dr. Kwon was selected to serve as a director of the
Company, nor is Dr. Kwon a party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the Company. As a non-employee director, Dr. Kwon is eligible to participate in the Amended and Restated ADMA Biologics,
Inc. 2014 Omnibus Incentive Compensation Plan. For his service on the Board, Dr. Kwon will receive compensation in accordance with the Company’s general policies for compensation of non-employee directors, including, without limitation, an initial
grant of options to purchase 93,500 shares of the Company’s common stock upon joining the Board.
The Company issued a press release on October 18, 2021 announcing Dr. Kwon’s appointment to the Board. A copy of the press release is attached to this
Form 8-K as Exhibit 99.1 and incorporated by reference herein.
| Item 9.01 |
Exhibits.
|
(d) Exhibits
|
Exhibit No.
|
Description
|
|
Press Release, dated October 18, 2021
|
|
|
104
|
Cover Page Interactive Data File (embedded with the Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
October 18, 2021
|
ADMA Biologics, Inc.
|
|||
|
By:
|
/s/ Brian Lenz
|
|||
|
Name:
|
Brian Lenz
|
|||
|
Title:
|
Executive Vice President and
Chief Financial Officer
|
|||
3
Exhibit 99.1
ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.
RAMSEY, N.J. and BOCA RATON, Fla., October 18, 2021 – ADMA Biologics,
Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the appointment of Young T. Kwon, Ph.D., to
its Board of Directors. Dr. Kwon is a highly accomplished corporate executive in the life sciences and biotechnology space. He brings over a decade of expertise in strategic advising, corporate finance and business development transactions to
ADMA’s Board.
“Young is a recognized leader in the healthcare sector and his deep strategic and financial experience will offer invaluable perspectives as ADMA continues to increase
revenues for its commercial immunoglobulin (“IG”) product portfolio,” said Steven Elms, Chairman of ADMA’s Board of Directors. “Over the course of his career, Dr. Kwon has held a variety of C-suite leadership positions, in which he played pivotal
roles involving multibillion-dollar mergers and acquisitions. We look forward to Young’s expert engagement and assistance in guiding our objectives, including the Company’s evaluation of alternative business opportunities.”
“ADMA has established a strong foundation which has enabled the Company to successfully penetrate the rapidly growing U.S. IG market. I am honored to join the Board
during this important phase of the Company’s growth and offering advice and guidance on ways to unlock unrealized value from the Company’s vertically integrated biologics manufacturing platform. I very much look forward to leveraging my professional
experience to advance ADMA’s strategic and financial goals and ultimately maximizing value for shareholders,” said Dr. Kwon.
Dr. Kwon is presently an operating partner at Lightstone Ventures (“LSV”), assisting the LSV biopharmaceutical team with deal sourcing, due diligence, and portfolio
management. Prior to LSV, he served as Chief Financial and Business Officer at Momenta Pharmaceuticals, a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, where he most
recently led the sale of Momenta to Johnson & Johnson for approximately $6.5 billion in 2020. At Momenta, he led all finance-related and business development initiatives, including those pertaining to the development efforts of M254, Momenta’s
hypersialylated IG clinical program. Prior to Momenta, Dr. Kwon was a business development professional at Biogen, driving a variety of transactions.
Dr. Kwon received a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University and a B.S. in Biology from MIT.
1
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the
treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the
treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous,
human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification
facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s
mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient
populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its
products and product candidates. For more information, please visit www.admabiologics.com.
|
COMPANY CONTACT:
|
|
Skyler Bloom
|
|
Director, Investor Relations and Corporate Strategy | 201-478-5552 | sbloom@admabio.com
|
|
INVESTOR RELATIONS CONTACT:
|
|
Michelle Pappanastos
|
|
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com
|
2